The historical rank and industry rank for Virax Biolabs Group's Gross Margin % or its related term are showing as below:
VRAX'
s Gross Margin % Range Over the Past 10 Years
Min: -1533.33 Med: -7.26 Max: 46
Current: -1533.33
During the past 6 years, the highestGross Margin % of Virax Biolabs Group was 46.00%. The lowest was -1533.33%. And the median was -7.26%.
VRAX's Gross Margin % is ranked worse than 99.32% of 730
companies
in the Biotechnology industry
Industry Median: 60.91
vs VRAX: -1533.33
Virax Biolabs Group had a gross margin of 50.00% for the quarter that ended in Sep. 2025 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Virax Biolabs Group was 0.00% per year.
Virax Biolabs Group (NAS:VRAX) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Virax Biolabs Group had a gross margin of 50.00% for the quarter that ended in Sep. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Virax Biolabs Group Gross Margin % Related Terms
Virax Biolabs Group Gross Margin % Historical Data
* Premium members only.
The historical data trend for Virax Biolabs Group's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VRAX vs BBLG, PKTX, OGEN: Gross Margin % Comparison
For the Biotechnology subindustry, Virax Biolabs Group's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Virax Biolabs Group Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Virax Biolabs Group's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Virax Biolabs Group's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Virax Biolabs Group (VRAX) has a Gross Margin % of 50.00% as of Sep. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Virax Biolabs Group and its competitors. According to the industry distribution chart, Virax Biolabs Group ranks #725 out of 730 companies in the Biotechnology industry, placing it in the top 99.3%.
Is Virax Biolabs Group's Gross Margin % too high?
Virax Biolabs Group's current Gross Margin % is 50.00%. The Biotechnology industry median Gross Margin % is 60.91. Virax Biolabs Group's value of 50.00% is 17.9% below this industry median. Based on the distribution chart, Virax Biolabs Group ranks #725 out of 730 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Virax Biolabs Group has a GF Score™ of 29/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Virax Biolabs Group's Gross Margin % compare to BBLG and PKTX?
According to the Biotechnology industry distribution chart, Virax Biolabs Group ranks #725 out of 730 companies for Gross Margin %. This places Virax Biolabs Group in the lower half of its industry. The industry median Gross Margin % is 60.91. Virax Biolabs Group's value of 50.00% is 17.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 730 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Virax Biolabs Group's current Gross Margin % of 50.00% is 17.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Virax Biolabs Group and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Virax Biolabs Group's current Gross Margin % is 50.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Virax Biolabs Group stock overvalued right now?
Based on GuruFocus' analysis, Virax Biolabs Group (VRAX) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.15, compared to a current price of $3.09 — trading 168.7% above its estimated fair value. The current Gross Margin % is 50.00% and 17.9% below the Biotechnology industry median of 60.91. Virax Biolabs Group's overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Virax Biolabs Group (VRAX), the current Gross Margin % is 50.00% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Virax Biolabs Group (VRAX) Overvalued in 2026?
Based on GuruFocus' analysis, Virax Biolabs Group stock appears to be overvalued.
The current stock price of $3.09 is trading 168.7% above its estimated GF Value™ of $1.15.
GuruFocus considers Virax Biolabs Group to be Significantly Overvalued.
Key valuation signals for VRAX:
Gross Margin %: 50.00%
GF Value™: $1.15 vs. price of $3.09 (168.7% above fair value)
Industry Position: 17.9% below the Biotechnology median (#725 of 730)
No single metric tells the full story. See the VRAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Virax Biolabs Group Ltd is an inventive biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Through its ViraxImmune platform and ImmuneSelect portfolio of research-use-only (RUO) products and services, the Company is building an immune-profiling offering that spans RUO assays, preclinical immunology services and, longer term, T cell-based diagnostics aimed at post-acute infection syndromes (PAIS) such as Long COVID and other chronic conditions linked to immune dysregulation.
29GF Score
Get the complete analysis for VRAX
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VRAX has been successfully added to your 
